Catenin Beta 1 (Beta Catenin or CTNNB1) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Catenin Beta 1 (Beta Catenin or CTNNB1)- Pipeline Review, H2 2019’, provides in depth analysis on Catenin Beta 1 (Beta Catenin or CTNNB1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Gastrointestinal, Non Malignant Disorders and Respiratory under development targeting Catenin Beta 1 (Beta Catenin or CTNNB1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1)

– The report reviews Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Aileron Therapeutics Inc

Boston Biomedical Inc

Circle Pharma Inc

Dicerna Pharmaceuticals Inc

Fog Pharmaceuticals Inc

iBeCa Therapeutics

PRISM Pharma Co Ltd

Propanc Biopharma Inc

Sapience Therapeutics Inc

Venn Therapeutics LLC

WntRx Pharmaceuticals Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Catenin Beta 1 (Beta Catenin or CTNNB1) - Overview

Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development

Aileron Therapeutics Inc

Boston Biomedical Inc

Circle Pharma Inc

Fog Pharmaceuticals Inc

Marina Biotech Inc

Propanc Biopharma Inc

Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles

BBI-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exisulind - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nefopam hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides for Hepatoblastoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRI-724 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRP - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit CTNNB1 for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit Beta Catenin for Solid Tumor and Blood Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTX-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WX-024 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Catenin Beta 1 (Beta Catenin or CTNNB1) - Dormant Products

Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones

Featured News & Press Releases

Aug 09, 2018: Propanc Biopharma selected to present at the 25th Annual NewsMakers in the Biotech Industry

Apr 10, 2018: Propanc Biopharma Completes Scientific Advice Meeting with MHRA

Mar 14, 2018: Propanc Biopharma Completes Successful Reproduction Run for PRP

Feb 20, 2018: Propanc Biopharma Receives Allowance of Key Patent Application in the EU

Dec 28, 2017: Propanc Biopharma to Present at the 10th Annual Biotech Showcase 2018

Nov 27, 2017: Propanc Biopharma to Present at the 10th Annual LD Micro Main Event

Oct 19, 2017: Propanc Biopharma Publishes Key Scientific Data in Peer Reviewed Journal

Sep 27, 2017: Propanc Biopharma Highlights Therapeutic Potential of PRP

Aug 30, 2017: Propanc Biopharma Provides Shareholder Update for PRP on Current and Future Activities Leading to Commencement of First-In-Human Studies

Aug 02, 2017: Propanc Biopharma Confirms No Treatment Related Findings for PRP in 28-Day Repeat-Dose Toxicity Study

Jul 27, 2017: Propanc Biopharma Provides Shareholder Update on R&D Activities for PRP

Jul 20, 2017: Propanc Biopharma Receives Acceptance of Key Patent Application for Cancer Treatment in China

Jun 27, 2017: ScarX Achieves Full Enrollment in Human Scar Reduction Trial Safety and Efficacy Results Targeted for Late 2017

Jun 26, 2017: Propanc Biopharma Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer

Jun 09, 2017: Propanc Biopharma Makes Significant Progress with PCT Patent Application

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Aileron Therapeutics Inc, H2 2019

Pipeline by Boston Biomedical Inc, H2 2019

Pipeline by Circle Pharma Inc, H2 2019

Pipeline by Dicerna Pharmaceuticals Inc, H2 2019

Pipeline by Fog Pharmaceuticals Inc, H2 2019

Pipeline by iBeCa Therapeutics, H2 2019

Pipeline by PRISM Pharma Co Ltd, H2 2019

Pipeline by Propanc Biopharma Inc, H2 2019

Pipeline by Sapience Therapeutics Inc, H2 2019

Pipeline by Venn Therapeutics LLC, H2 2019

Pipeline by WntRx Pharmaceuticals Inc, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports